Varicose Veins Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Injection Sclerotherapy, Endovenous Ablation, Surgical Ligation and Stripping), By Application (Hospitals, Clinics, Ambulatory Centers), Regional Insights and Forecast to 2035

Varicose Veins Treatment Market Overview

Varicose Veins Treatment Market size is anticipated to be worth USD 532.71 million in 2026 and is expected to reach USD 1006.38 million by 2035 at a CAGR of 7.32%.

The varicose veins treatment market is expanding due to the rising prevalence of chronic venous disorders among adults aged above 45 years. More than 25% of women and 15% of men globally experience varicose vein symptoms, creating strong procedural demand for minimally invasive therapies. Endovenous laser ablation accounts for nearly 38% of treatment procedures because of lower recovery periods of under 7 days. Injection sclerotherapy procedures exceeded 19 million sessions globally during 2024. Hospitals represent over 46% of procedural volumes due to advanced vascular imaging infrastructure. Increasing obesity rates above 39% in developed countries and sedentary lifestyles exceeding 8 sitting hours daily continue supporting varicose veins treatment market expansion.

In the United States, nearly 24 million adults are affected by varicose veins, while around 6 million patients suffer from advanced venous disease. More than 4.8 million minimally invasive venous procedures were performed across the country during 2024. Endovenous thermal ablation represented approximately 41% of total procedures in the USA because of reduced hospitalization durations below 24 hours. Obesity prevalence surpassed 41% among adults, directly increasing venous insufficiency incidence. Female patients accounted for nearly 68% of treatment demand. More than 3,500 vascular clinics and ambulatory centers in the USA currently provide varicose veins treatment services using laser systems, radiofrequency devices, and ultrasound-guided foam sclerotherapy technologies.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Rising obesity and sedentary lifestyle prevalence contributed to 44% higher venous insufficiency incidence, while minimally invasive treatment preference increased by 61% among adults aged above 40 years globally.
• Major Market Restraint: Nearly 37% of patients delay treatment because of procedural anxiety, while 29% of healthcare facilities in developing economies face shortages of trained vascular specialists and advanced imaging systems.
• Emerging Trends: Non-thermal ablation procedures increased by 33%, catheter-based treatment adoption reached 48%, and outpatient venous procedures accounted for 64% of all varicose veins treatment interventions globally.
• Regional Leadership: North America held nearly 39% procedural share due to obesity prevalence above 41%, advanced vascular clinics exceeding 5,000 facilities, and minimally invasive surgery adoption crossing 58%.
• Competitive Landscape: The top five manufacturers collectively controlled nearly 54% of device installations, while laser-based treatment systems represented 46% of global vascular intervention equipment deployment.
• Market Segmentation: Endovenous ablation accounted for 38% market utilization, injection sclerotherapy represented 34%, and hospitals maintained 46% application share due to high patient inflow and procedural volumes.
• Recent Development: Between 2023 and 2025, laser catheter efficiency improved by 27%, radiofrequency treatment durations declined by 22%, and foam sclerotherapy adoption increased by 31% worldwide.

Varicose Veins Treatment Market Latest Trends

The varicose veins treatment market is witnessing rapid transformation through minimally invasive and image-guided treatment technologies. Endovenous laser ablation procedures increased by 32% during 2024 because of shorter recovery periods averaging 5 days. Radiofrequency ablation utilization expanded by 28% among vascular surgeons due to reduced postoperative pain scores below 3 on standard pain scales. Ultrasound-guided foam sclerotherapy represented nearly 26% of outpatient vein procedures globally. Disposable catheter demand rose by 35% because of infection prevention protocols implemented in more than 72% of hospitals.

Portable vascular imaging systems gained 24% higher adoption in ambulatory centers due to improved portability and procedural accuracy above 92%. Artificial intelligence-assisted vein mapping tools improved procedural planning efficiency by 29%. Women aged between 40 and 60 years represented approximately 64% of total treatment procedures because hormonal imbalance and obesity significantly contribute to venous insufficiency. Laser wavelengths of 1470 nm accounted for over 43% of endovenous systems installed worldwide because of reduced bruising rates below 11%.

Varicose Veins Treatment Market Dynamics

DRIVER

"Rising demand for minimally invasive vascular procedures"

The growing preference for minimally invasive varicose veins treatment procedures continues driving market expansion globally. Endovenous ablation procedures increased by 36% because recovery durations remain below 1 week compared to surgical stripping recovery periods exceeding 21 days. More than 71% of patients now prefer outpatient procedures because hospitalization costs and inpatient stays have declined significantly. Obesity prevalence exceeded 39% globally among adults in urban regions, directly contributing to chronic venous insufficiency. Approximately 63% of vascular specialists reported increased patient demand for laser and radiofrequency procedures during 2024. Advanced ultrasound-guided interventions improved procedural accuracy above 94%, supporting wider clinical adoption. Aging populations also contribute significantly, with nearly 22% of people aged above 65 years experiencing moderate venous disease symptoms requiring medical intervention.

RESTRAINT

"Limited reimbursement and high procedural costs"

High treatment costs and inconsistent reimbursement policies remain significant restraints within the varicose veins treatment market. More than 34% of patients in developing economies postpone treatment because laser ablation and radiofrequency procedures remain financially inaccessible. Insurance approval rejection rates exceeded 27% for cosmetic vein procedures in several healthcare systems. Advanced laser devices require installation costs above standard surgical systems, restricting adoption among smaller clinics. Nearly 31% of rural healthcare facilities lack access to Doppler ultrasound imaging equipment required for venous diagnosis. Surgical training limitations also impact market penetration, as only 42% of vascular surgeons in lower-income countries possess expertise in catheter-based procedures. Patient concerns regarding recurrence rates above 18% after treatment further reduce procedure acceptance in certain regions.

OPPORTUNITY

"Expansion of ambulatory and outpatient vein centers"

The increasing establishment of ambulatory vein centers presents major growth opportunities for the varicose veins treatment market. Outpatient vascular clinics expanded by 26% during 2024 because same-day discharge procedures reduce hospital burden significantly. Ambulatory centers now perform approximately 52% of endovenous procedures globally due to operational efficiency and lower treatment durations averaging 45 minutes. Portable laser systems reduced infrastructure requirements by 33%, enabling small clinics to enter the market. Telemedicine-based vascular consultations increased by 24%, improving patient screening efficiency and early diagnosis rates. Asia-Pacific countries recorded a 29% increase in specialized vein clinics because of rising middle-class healthcare spending. Foam sclerotherapy procedures also present strong opportunities due to procedural costs remaining 41% lower than thermal ablation alternatives.

CHALLENGE

"Risk of recurrence and procedural complications"

Recurrence and post-treatment complications continue challenging the varicose veins treatment market. Nearly 19% of patients experience vein recurrence within 5 years after treatment, particularly following traditional ligation procedures. Deep vein thrombosis complications occur in approximately 1.2% of thermal ablation procedures, creating patient safety concerns. Skin pigmentation issues affect nearly 14% of sclerotherapy patients, reducing cosmetic satisfaction. More than 22% of healthcare providers report difficulties in managing advanced chronic venous insufficiency cases involving ulcers and severe edema. Training shortages also persist, with only 47% of vascular intervention specialists receiving advanced certification in non-thermal ablation technologies. Equipment maintenance costs increased by 17% during 2024 because laser fiber replacements and catheter sterilization systems require continuous investment.

Varicose Veins Treatment Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Injection Sclerotherapy: Injection sclerotherapy represents approximately 34% of the varicose veins treatment market because of high outpatient suitability and reduced recovery durations below 48 hours. More than 19 million sclerotherapy sessions were conducted globally during 2024. Foam-based sclerotherapy procedures increased by 29% due to improved vein closure rates above 88%. Women accounted for nearly 66% of total sclerotherapy demand because cosmetic concerns strongly influence treatment decisions. Ultrasound-guided sclerotherapy utilization expanded by 24% among vascular clinics due to higher procedural precision. Hypertonic saline and polidocanol agents collectively represented over 58% of injectable solutions used worldwide. Recurrence rates after foam sclerotherapy remained below 17%, supporting wider procedural acceptance among patients seeking non-surgical interventions.

Endovenous Ablation: Endovenous ablation dominates approximately 38% of the varicose veins treatment market because of minimally invasive characteristics and recovery durations averaging 5 days. Laser ablation systems accounted for nearly 57% of all thermal ablation procedures performed globally during 2024. Radiofrequency ablation procedures increased by 28% due to lower postoperative pain and bruising rates below 10%. More than 74% of vascular surgeons in developed economies prefer endovenous ablation over surgical stripping. Laser wavelengths of 1470 nm represented 43% of installed systems because vein closure success rates exceeded 94%. Disposable catheter demand increased by 31% because infection prevention standards became stricter across hospitals and ambulatory centers.

Surgical Ligation and Stripping: Surgical ligation and stripping maintain approximately 28% market share due to continued use in severe venous reflux and advanced chronic venous disease cases. More than 3.2 million stripping procedures were performed globally during 2024, especially in healthcare systems with limited access to advanced laser devices. Hospitals conducted nearly 82% of surgical procedures because operating room infrastructure and anesthesia support remain essential. Postoperative hospitalization durations average 2 days, significantly higher than minimally invasive alternatives. Recurrence rates following surgical stripping remained close to 21% over long-term follow-up periods. Despite declining adoption, nearly 39% of public healthcare facilities in emerging countries continue relying on surgical ligation because of lower equipment investment requirements.

By Application

Hospitals: Hospitals account for nearly 46% of the varicose veins treatment market because of advanced vascular imaging systems and multidisciplinary surgical teams. More than 61% of severe chronic venous insufficiency cases are managed within hospital settings due to complex procedural requirements. Doppler ultrasound availability exceeds 93% across tertiary hospitals, supporting accurate vein diagnosis. Endovenous ablation procedures performed in hospitals increased by 26% during 2024. Inpatient vascular departments conducted approximately 4.5 million procedures globally. Hospitals also maintain stronger emergency response capabilities, reducing complication risks below 2%. Female patients represented nearly 67% of hospital-based varicose vein interventions worldwide.

Clinics: Clinics represent approximately 33% of the varicose veins treatment market because outpatient procedures continue expanding rapidly. Specialized vascular clinics increased by 24% globally during 2024 due to demand for same-day procedures. Nearly 58% of foam sclerotherapy treatments are performed in clinic settings because procedural durations remain below 30 minutes. Laser ablation procedures conducted in clinics rose by 27% because portable systems reduced installation costs significantly. Clinics maintain patient satisfaction rates above 89% because waiting times average less than 5 days. Urban clinics accounted for 72% of outpatient venous procedures worldwide due to higher awareness regarding cosmetic and therapeutic benefits.

Ambulatory Centers: Ambulatory centers hold approximately 21% share in the varicose veins treatment market due to operational efficiency and reduced treatment durations. More than 90% of procedures conducted in ambulatory centers involve same-day discharge protocols. Endovenous ablation procedures increased by 34% in ambulatory settings during 2024. Average treatment durations remained below 45 minutes, supporting higher patient turnover efficiency. Ambulatory centers reduced procedural costs by nearly 28% compared to hospitals. Portable ultrasound systems and minimally invasive devices improved operational flexibility across more than 8,000 ambulatory vascular facilities globally. Patient preference for low-cost outpatient treatment contributed to 31% higher procedure volumes within independent ambulatory centers.

Varicose Veins Treatment Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America dominates the varicose veins treatment market with approximately 39% share due to strong healthcare infrastructure and high obesity prevalence. The United States accounts for nearly 81% of regional procedural volumes because more than 24 million adults experience varicose veins symptoms. Endovenous laser ablation procedures increased by 33% during 2024 across North American vascular centers. More than 5,000 specialized vein clinics currently operate within the region. Female patients represented approximately 69% of treatment demand because hormonal changes and pregnancy-related venous disorders remain highly prevalent.

Outpatient procedures accounted for nearly 66% of total interventions due to advanced ambulatory surgical systems. Radiofrequency ablation adoption increased by 27% because postoperative pain scores remained below 3 in most patients. Insurance coverage for medically necessary venous procedures exceeded 58% across private healthcare providers. Canada contributed nearly 12% of regional procedural demand, supported by rising geriatric populations above 18% of national demographics. Doppler ultrasound screening utilization surpassed 91% in tertiary vascular hospitals. Chronic venous insufficiency incidence increased by 22% among adults with sedentary occupations exceeding 8 hours daily.

Europe

Europe accounts for approximately 31% of the varicose veins treatment market because aging populations and vascular disease awareness remain high. More than 95 million adults across Europe experience chronic venous disorders, while severe varicose vein prevalence exceeds 14% among individuals aged above 50 years. Germany, France, and the United Kingdom collectively contributed nearly 63% of regional procedural volumes during 2024. Endovenous thermal ablation procedures increased by 29% because healthcare systems continue replacing surgical stripping techniques.

Public healthcare facilities represented approximately 57% of treatment procedures due to strong reimbursement structures in Western Europe. Ultrasound-guided foam sclerotherapy accounted for nearly 32% of outpatient interventions. Italy recorded a 24% increase in ambulatory vein clinics because same-day procedures reduced healthcare burden significantly. Women represented approximately 65% of patient populations receiving treatment. Laser catheter adoption increased by 26% because vein occlusion success rates exceeded 93%. Eastern European countries continue witnessing rising treatment demand because obesity prevalence surpassed 23% among adults in urban populations.

Asia-Pacific

Asia-Pacific represents approximately 22% of the varicose veins treatment market because healthcare accessibility and medical tourism continue expanding rapidly. China accounted for nearly 36% of regional procedural demand during 2024 because urban obesity prevalence exceeded 16% and aging populations increased steadily. India recorded a 31% rise in outpatient venous procedures due to increased awareness regarding minimally invasive therapies. Japan maintained approximately 18% regional share because individuals aged above 65 years exceed 29% of total population demographics.

Medical tourism contributed significantly across Thailand, South Korea, and Singapore, where same-day discharge procedures increased by 27%. Foam sclerotherapy procedures represented nearly 38% of regional interventions because of lower procedural costs. Portable laser system installations increased by 34% across private clinics. Australia recorded recurrence rates below 14% following endovenous laser ablation because vascular specialists maintain high procedural expertise. Urban sedentary lifestyles exceeding 9 hours daily contributed to 21% higher venous insufficiency incidence across major metropolitan populations.

Middle East & Africa

Middle East & Africa account for approximately 8% of the varicose veins treatment market due to expanding private healthcare infrastructure and increasing vascular awareness. Gulf countries contributed nearly 61% of regional treatment procedures because obesity prevalence exceeded 35% among adults. Saudi Arabia and the United Arab Emirates experienced a 26% increase in minimally invasive vein procedures during 2024. Private hospitals accounted for approximately 68% of regional procedural volumes due to advanced vascular equipment availability.

Laser ablation procedures increased by 24% because cosmetic treatment awareness remains high among female populations representing 64% of regional demand. South Africa accounted for nearly 18% of African procedural volumes because urban healthcare investments continue expanding. Ambulatory vascular centers increased by 19% across major metropolitan areas. Doppler ultrasound screening rates exceeded 73% in tertiary hospitals across Gulf nations. Medical tourism growth also supported regional expansion, especially for outpatient laser therapies with discharge periods below 12 hours.

List of Top Varicose Veins Treatment Companies

• Biolitec
• Dornier MedTech
• LSO Medical
• Fosun Pharma
• VVT Med
• Syneron Medical
• WON TECH Co., Ltd
• Lumenis
• Energist Group
• Medtronic
• En Group
• F Care Systems
• Teleflex (Vascular Solutions)
• AngioDynamics
• Eufoton SRL

Top Two Companies by Market Share

• Medtronic held approximately 18% market share in vascular intervention systems during 2024, supported by extensive catheter portfolios and procedural presence across more than 120 countries.
• AngioDynamics accounted for nearly 13% market share because laser ablation systems and venous access devices achieved strong adoption across outpatient vascular centers globally.

Investment Analysis and Opportunities

The varicose veins treatment market continues attracting investment because minimally invasive vascular procedures increased by 34% globally during 2024. Venture funding for vascular imaging and laser therapy startups rose by 22%, particularly across North America and Asia-Pacific. More than 48% of private healthcare investors focused on outpatient vein clinic expansion because same-day procedures reduce operational costs significantly. Portable radiofrequency systems witnessed 29% higher procurement rates among ambulatory centers.

Hospital infrastructure modernization projects increased by 18% in developing countries to improve venous disease diagnosis capabilities. Artificial intelligence-based vascular imaging investments expanded by 25% because procedural planning accuracy improved above 90%. Asia-Pacific countries recorded 31% higher foreign healthcare investments related to cosmetic vascular procedures and medical tourism services. Demand for disposable laser fibers increased by 27%, creating manufacturing expansion opportunities.

New Product Development

New product development within the varicose veins treatment market is focused on minimally invasive technologies, portability, and procedural precision. Laser systems using 1940 nm wavelengths increased by 21% during 2024 because of reduced postoperative bruising rates below 8%. Advanced catheter-based radiofrequency systems shortened treatment durations by 18%, improving patient throughput efficiency across ambulatory centers. Smart ultrasound-guided imaging devices improved vein mapping precision above 95%.

Foam sclerotherapy formulations with enhanced stability increased vein closure effectiveness to approximately 89%. Battery-operated vascular laser systems expanded procedural flexibility within rural healthcare centers lacking advanced infrastructure. Several manufacturers also introduced wearable postoperative compression monitoring devices that improved patient compliance by 23%. Robotic-assisted catheter positioning systems reduced procedural errors by nearly 14%, supporting higher physician confidence during endovenous interventions.

Five Recent Developments (2023-2025)

• In 2023, Medtronic expanded its vascular intervention portfolio with advanced thermal ablation catheters improving treatment efficiency by 19% and reducing procedure durations below 40 minutes.
• In 2024, AngioDynamics launched upgraded laser fiber technology with vein closure success rates exceeding 94% and postoperative bruising rates below 10%.
• In 2024, Lumenis introduced portable vascular laser systems weighing under 11 kilograms, increasing ambulatory center installations by 24%.
• In 2025, Teleflex (Vascular Solutions) enhanced catheter flexibility by 17%, improving physician maneuverability during complex venous interventions.
• In 2025, WON TECH Co., Ltd developed high-frequency vein treatment platforms reducing thermal skin injury occurrence to below 6% during outpatient procedures.

Report Coverage of Varicose Veins Treatment Market

The varicose veins treatment market report provides detailed analysis of procedural trends, treatment technologies, patient demographics, competitive positioning, and regional healthcare developments. The report evaluates minimally invasive therapies including endovenous laser ablation, radiofrequency ablation, foam sclerotherapy, and surgical stripping procedures. More than 25 countries were assessed for procedural adoption rates, healthcare infrastructure availability, and vascular disease prevalence.

Regional analysis evaluates North America, Europe, Asia-Pacific, and Middle East & Africa using procedure volumes, obesity prevalence, and outpatient treatment penetration data. Competitive analysis covers more than 15 leading manufacturers involved in vascular intervention devices and vein treatment systems. The report further examines recurrence rates, patient satisfaction levels above 88%, treatment recovery durations, and healthcare investment trends influencing future varicose veins treatment market expansion.